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Survival following gamma knife radiosurgery for
brain metastasis from breast cancer
Jerry J Jaboin1†, Daniel J Ferraro1†, Todd A DeWees1, Keith M Rich2, Michael R Chicoine2, Joshua L Dowling2,
David B Mansur3, Robert E Drzymala1, Joseph R Simpson1, William J Magnuson4, Anushka H Patel5 and Imran Zoberi1*
Abstract
Background: Breast cancer is the second most common cause of brain metastases in the United States. Although
breast cancer induced brain metastases represent an incurable condition, some patients experience prolonged survival.
In this retrospective study, we examine a cohort of patients with brain metastases from breast cancer treated with
Gamma Knife stereotactic radiosurgery to identify factors that predict better outcomes.
Methods: A retrospective database of 100 patients treated for brain metastases due to breast cancer via Gamma Knife
radiosurgery (GKS) from July 1998 through March 2009 was reviewed. Patients who received radiosurgery as sole
treatment, as a planned boost after whole brain radiotherapy or surgical resection, or as salvage after prior whole brain
radiation therapy (WBRT) or surgical resection were included. Prognostic factors identified to be significant for survival in
previous brain metastasis studies were analyzed for significance by univariate and multivariate Cox analysis.
Results: Overall, the median brain progression-free survival time was 7.1 months and the median survival time was
12.3 months. No prognostic variables were significant for brain progression-free survival. For patients treated with a
planned GKS after WBRT, GKS as sole treatment, GKS salvage after WBRT, GKS boost after surgery, or GKS for surgical
salvage the median survival times (MSTs) were as follows: 12.2 months, 12.4 months, 9.5 months, 27.6 months and
33.4 months respectively. Differences between the groups were not significant (p = 0.06); however, GKS boost after
surgery and GKS for salvage after surgery did have a trend toward better overall survival.
The MST for patients of age <65 years was 14.5 months, compared to age ≥65 which was 7.7 months (p = 0.06) and
remained a significant prognostic factor for overall survival on multivariate analysis. The MST for patients with a single
lesion was 16.9 months, not significantly different than the MST of 14.5 months for patients with 2–3 lesions. However
patients with >3 lesions had a MST of 5.9 months, which was significantly worse. Breast cancer subtype as
approximated by biomarkers and KPS were not significant predictors of overall survival and stage at initial diagnosis was
inversely associated with survival.
Conclusion: Stereotactic radiosurgery offers good local control and prolonged survival in selected patients. Age and
number of lesions are strong predictors of overall survival.
Keywords: Gamma knife, Stereotactic radiosurgery, GKS, Breast cancer, Brain metastasis
Introduction
Breast cancer is the most common cancer among women,
and the second most common source of brain metastases
in the United States. While major advances in the treatment
of breast cancer have occurred in the past two decades, a
significant number of women will continue to succumb to
the disease after metastatic spread. Approximately 10–15%
of women diagnosed with breast cancer will develop symp-
tomatic brain metastases, and approximately 30% of breast
cancer patients will have brain disease at autopsy. Young
age, estrogen receptor negative status, and HER2 overex-
pression have all been associated with increased risk for the
development of breast cancer CNS metastases [1,2].
Supportive care and whole brain radiation therapy
(WBRT) have a major role in the management of brain
metastasis; however, the survival of most patients with
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brain metastasis remains limited. In this population the
Radiation Therapy Oncology Group (RTOG) has identi-
fied age, performance status, control of the primary tumor,
and presence of extracranial disease as prognostic factors
for survival [3,4] and created a recursive partitioning
analysis (RPA) to predict survival using these factors. Un-
fortunately this model demonstrated that even the most
favorable patients had a median survival of only 7.1 months
[3]. The Breast Specific Graded Prognostic Assessment
(BS-GPA) showed patients with CNS metastases due to
breast cancer to have a median survival of 13.8 months,
with the most favorable group having a median survival of
25.3 months [5]. These median survival times were much
longer than that predicted by the RTOG RPA and suggest
that patients with CNS metastases due to breast cancer
survive longer than patients with CNS metastases as a
whole. The Breast Specific Graded Prognostic Assessment
is defined in Sperduto et al. 2012 and utilizes Karnofsky
Performance Status (KPS), Genetic subtype, and Age to
risk stratify patients into 4 groups predictive for median
survival [5].
In an attempt to capitalize on these results, some pa-
tients with good performance status, limited extracranial
disease, and few brain lesions have been treated more ag-
gressively with stereotactic radiosurgery (SRS). Originally
developed by neurosurgeon Lars Leksell [6], stereotactic
radiosurgery delivers a single high dose of ionizing radi-
ation to a small volume in a highly accurate manner. Cur-
rently SRS is most often performed via a linear accelerator
or a Gamma Knife (Elekta Instruments, Norcross, GA).
Defining optimal situations for SRS has proved difficult
with practitioners using SRS as a planned boost following
WBRT [7], a planned boost to a surgical bed [8,9], sole
treatment [10], or as a salvage intervention [11]. Here we
report our experience treating CNS breast metastasis via
Gamma Knife Radiosurgery.
Methods
Patient selection
Patients with a prior pathologic diagnosis of breast cancer
treated with Gamma Knife radiosurgery (GKS) for breast
cancer related brain metastases at the Siteman Cancer
Center at Barnes-Jewish Hospital/Washington University
Medical Center (BJH/WUMC) between July 1998 and
March 2009 were retrospectively reviewed. Our Gamma
Knife center is a shared community resource utilized by
qualified neurosurgeons and radiation oncologists from
the Greater Saint Louis area. This review was restricted to
patients treated by neurosurgical and radiation oncology
faculty of Washington University School of Medicine
(WUSM). There were no other exclusions. The primary
endpoint of the study was overall survival with the rate of
disease recurrence in the brain being a secondary end-
point. Patients who had previous whole brain radiotherapy
or prior surgical resection were included. Patients who
underwent surgical resection were medically stable at the
time of surgery and believed to have life expectancies
>6 months. Patients with evidence of residual disease in
the surgical field on the first postoperative MRI were
classified as having a sub-total resection and not recurrent
disease. Breast cancer subtype for invasive cancers was
approximated using estrogen receptor (ER), progesterone
receptor (PR), and Human Epidermal growth factor Re-
ceptor 2 (HER2/neu) status [8]. Patients were followed
serially in both the Neurosurgical and Radiation Oncology
clinics. Patients were assessed for KPS and neurological
symptoms. Patients were classified using the RTOG RPA,
GPA, and BS-GPA classification system. Washington Uni-
versity School of Medicine Human Research Protection
Office reviewed and approved this study (Protocol#
201106242).
Radiosurgical technique
Stereotactic radiosurgery was performed at the Gamma
Knife of Saint Louis facility at BJH/WUMC. We catego-
rized radiosurgery by its intent as Sole Treatment, Planned
Boost after Whole Brain Radiation, Planned Boost after
Surgery or Salvage Treatment. We defined Sole Treatment
as being GKS administered without any prior radiation
therapy, surgery, or chemotherapy specifically intended to
treat brain metastasis. A Planned Boost occurred within
two months of the completion of either WBRT or surgery.
Salvage treatment occurred in the setting of prior radiation
therapy, surgery, or chemotherapy for brain metastasis. All
patients were assigned to a treatment intent category based
on their clinical situation at their initial GKS treatment.
Any subsequent GKS treatments for a particular patient
were classified as an in-brain recurrence and not as inde-
pendent cases.
All patients underwent stereotactic radiosurgery with
the Gamma Knife (Elekta, Norcross, GA). From June 1998
to August 2002 this was a Model B while from August
2002 to April 2008 a Model C and afterwards a Perfexion.
All patients had intravenous access placed. A Leksell
frame was placed under local anesthesia often with a low,
intravenous dose of an anxiolytic. In the vast majority
of cases a computed tomography scan without contrast
and a contrast-enhanced magnetic resonance image were
obtained and images transferred to the GKS treatment
planning computer. The target(s) were contoured and a
radiosurgery plan was developed. In general, dose was se-
lected based on the recommendations from the SRS dose
escalation trial RTOG 90–05 [12]; tumor size, location,
and history of prior radiation therapy were considered in
selecting the prescription dose. The doses ranged from
10 to 24 Gy, The prescription dose was generally
prescribed to the 50% isodose line, which followed the
MR contrast enhanced tumor margin. Quality assurance
Jaboin et al. Radiation Oncology 2013, 8:131 Page 2 of 8
http://www.ro-journal.com/content/8/1/131
consisting of verification of patient name from all imaging,
patient orientation, MR fiducial alignment, patient identity
(patient name and birth date by all members of the treat-
ment team), and treatment specifications at the Gamma
Knife treatment console was done in all cases.
The medical record was retrospectively reviewed to
determine pretreatment patient and tumor characteris-
tics and the dates of time-to-event endpoints. The recur-
rence of treated disease, progression of known disease,
or the development of new brain metastasis was scored
as a failure for brain recurrence. Death from any cause
was a failure for overall survival. All times were mea-
sured from the date of radiosurgery.
Statistical analysis
Standard measures of central tendency and dispersal
were used to characterize patient and tumor parameters.
Survival time and time to CNS recurrence were calcu-
lated from the date of GKS. The Kaplan-Meier method
was used to describe time to brain recurrence and over-
all survival. The log-rank test was used to compare these
endpoints in univariate analysis while the Cox Propor-
tional Hazards method was used to analyze the effects of
multiple potential independent predictors on overall sur-
vival. Based on published literature, we analyzed several
known favorable predictors including: controlled extra-
cranial disease, number of brain metastases, no prior
whole brain radiotherapy, smaller total radiosurgery vol-
ume, HER2/neu overexpression, younger age, and good
performance status. Suspected predictive factors includ-
ing treatment intent and number of brain metastasis
were entered using stepwise deletion. Statistical tests
were performed using SAS version 9.2 (SAS Institute
Inc., Cary, NC). All statistical tests were two-sided with
p values < 0.05 deemed significant.
Results
Patient characteristics
One hundred consecutive breast cancer patients receiv-
ing Gamma Knife stereotactic radiosurgery (GKS) for brain
metastasis treated between July 1998 and March 2009 were
reviewed. All patients were female. The mean time from
the diagnosis of breast cancer to the detection of brain me-
tastasis was 48 months (median: 30.2 months), while the
mean time from diagnosis of breast cancer to radiosurgery
was 55 months (median: 37.4 months). The mean time
from diagnosis of brain metastases to GKS was 7 months
(median: 3.4 months). For GKS treatment, the mean
follow-up time was 18.3 months (median: 12.3 months).
Complete information regarding TNM (Tumor, Node and
Metastasis) staging was available in 87 patients while the
remaining 13 were only known to be M0 or M1 at diagno-
sis. In our cohort, 13% were Stage I, 27% Stage II, 34%
Stage III and 13% Stage IV with 85 patients having had M0
disease at the time of diagnosis. Detailed patient, tumor
and treatment characteristics are summarized in Table 1.
Radiosurgical parameters
All evaluated patients were treated with GKS as described
in the Methods section. The median tumor volume was
3.50 cm3 (range, 0.10–38.71). The median treatment vol-
ume was 3.69 cm3 (range, 0.12–141.4). The median num-
ber of treatment shots was 8 (range, 1–35). The median
number of lesions was 2 (range, 1–20). The median num-
ber of treated lesions was 2 (range, 1–12). The median
GKS prescription dose was 18 Gy to the 50% isodose line
(range, 10–24 Gy).
Table 1 Patient characteristics
Characteristics No. of patients (n = 100)
Age at GKS, mean (sd), y 51.8 (10.2)
M0 at diagnosis 85
Breast Cancer Subtype
Luminal A 15
Luminal B 20
HER2 33
Basal 27
Unknown 5
KPS score
70–80 73
90–100 27
Extracranial metastasis at time of GKS 71
RTOG RPA Class 1 24
RTOG RPA Class 2 76
Prior WBRT 64
Number of Brain Metastasis Treated
1 48
2 21
3 17
4 10
> = 5 4
Intent of Radiosurgery
Boost after Surgery 9
Boost after WBRT 25
Sole Treatment 26
Salvage after Surgery 3
Salvage after WBRT 37
Volume of Largest Lesion, mean (sd), mL 3.86 (4)
Abbreviations: GKS Gamma Knife radiosurgery, ER estrogen receptor, H2N
her-2/neu gene, KPS Karnofsky Performance Status, RPA Recursive partitioning
analysis, RTOG Radiation therapy oncology group, WBRT Whole brain
radiation therapy.
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General patient survival outcomes
Fifty-three patients had a CNS failure, however not all
received subsequent CNS treatment: 15 had subsequent
GKS, 1 had surgery, 9 had subsequent WBRT, 3 had
both WBRT and GKS. The median overall survival time
for our patient cohort was 12.3 months from the time of
GKS treatment. At our last update, 88 of our 100 pa-
tients were deceased. The median progression-free sur-
vival time was 7.1 months.
Patient outcomes based on treatment intent
The nine patients treated with a GKS boost after surgery
had a median survival time (MST) of 27.6 months. The
three patients undergoing GKS for surgical salvage had a
MST of 33.4 months. The 25 patients treated with a
planned GKS boost after whole brain radiation therapy
(WBRT) had a MST of 12.2 months. The 26 patients who
had GKS as sole treatment had a MST of 12.4 months, and
the 37 patients who had GKS for salvage after WBRT had
a MST of 9.5 months. There was no statistical significance
between the groups in terms of overall survival. Grouping
the overall cohort into those receiving GKS as salvage ther-
apy, sole therapy, or as a planned boost also resulted in
non-significantly different survival curves (Figure 1).
Patient outcomes based on known prognostic parameters
There was a significant difference in outcomes based on
the number of brain lesions (Chi square: 10.06, p = 0.01),
as shown in Figure 2. Patients with a single treated le-
sion had a MST of 16.9 months. To analyze the effect of
multiple lesions, we compared patients with >3 lesion
(MST: 5.9 months) and patients with 2–3 lesions (MST:
14.5 months) to patients with a single lesion. This
analysis demonstrated that patients with >3 lesions have a
significantly lower overall survival (HR = 2.42, p < 0.01),
while patients with 2–3 lesions show no significant differ-
ence in survival time (HR = 1.91, p = 0.49) as compared to
the patients with a single lesion.
The MST for patients with age <65 years was
14.5 months, and for patients with age ≥65 was 7.7 months
(Figure 3). While the data was not statistically significant,
there was a strong trend towards a difference in survival
(HR = 0.61, Chi square: 3.41, p = 0.06) in favor of lower
age, which did become significant on multivariate analysis
(HR = 0.28, Chi square 6.42, p = 0.01).
Patients were categorized into five tumor subtypes
based on surface receptor expression: luminal A, luminal
B, HER2/neu, basal, and unknown. The MST for luminal
A was 7.2 months, luminal B was 17.8 months, basal
was 8.1 months, HER2/neu was 21.7 months and un-
known was 7.8 months. Overall there was no difference
seen between these subtypes on univariate analysis (Chi
square: 6.51, p = 0.16).
Documented CNS failure occurred in 51.4% of the pa-
tients. CNS failure was associated with a significant in-
crease in MST, where patients with CNS failure had a
MST of 14.5 months and patients without CNS failure
had a MST of 6.54 months. There was a statistically sig-
nificant overall survival advantage seen for patients who
had documented CNS failure, as compared to those who
did not (HR = 0.56, p = 0.01). Multivariate analysis demon-
strated CNS failure to predict longer MST (Chi Square:
4.79, p = 0.03).
Stage at initial presentation predicted lower MSTs for
stage I after GKS for CNS disease. The MST for stage I
was 5.9 months, stage II was 14.4 months, stage III was
Figure 1 Overall survival of patients treated by GKS stratified by type of treatment.
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13.0 months, and stage IV was 9.8 months (Chi square:
9.88, p = 0.02). On multivariate analysis, stage remained
a significant predictor of overall survival (Chi Square:
8.67, p = 0.03).
Patient outcomes based on known prognostic assessments
The BS-GPA was predictive of survival outcomes (Chi
square: 11.36, p = 0.01, Figure 4). For patients with a BS-
GPA of 0–1 (Group 1), the MST was 6.4 months. For
the others: BS-GPA of 1.5–2.0 (Group 2) had a MST of
7.9 months, the BS-GPA of 2.5–3.0 (Group 3) had a
MST of 13.3 months, and those with a BS-GPA of 3.5–
4.0 (Group 4) had a MST of 21.1 months.
Discussion
Randomized trials have tested SRS with and without
WBRT [7,13]. These studies demonstrated median sur-
vival times between 6.5 to 8.0 months. It is difficult to
apply these outcomes to breast cancer patients, as they
comprised only 10% of those trial populations. However,
the data suggest that survival outcome in metastatic breast
cancer is heterogeneous. Some patients suffer from rapidly
progressive disease, but a significant number have a more
Figure 2 Overall survival of patients treated by GKS stratified by number of lesions. 0= > 3, 0.5 = 2–3, 1 = 1.
Figure 3 Overall survival of patients treated by GKS stratified by age. 1 = <65, 2= >/=65.
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indolent albeit ultimately fatal course [14,15]. Even in the
setting of brain metastasis, breast cancer has been shown
to be a favorable prognostic factor for survival [16]. It was
the impression of the study investigators that patients with
breast cancer treated with radiosurgery experienced rela-
tively long survival times compared to other types of
tumors. In an effort to quantify this impression we per-
formed a single institution retrospective review of breast
cancer patients treated with radiosurgery. Our goal was to
determine the influence of known and suspected prognos-
tic factors on survival and to characterize the survival
function in our patient population.
Prior retrospective studies have addressed outcomes
and prognostic factors for overall survival in patients
treated with GKS for breast cancer brain metastasis [17].
Kondziolka et al. reviewed outcomes for a cohort of
350 consecutive patients [18]. In this group, 64.9% had
undergone previous WBRT and 67% had multiple le-
sions, with 22% having ≥ 5 metastatic lesions treated.
Median survival was 11.2 months, and similar to our re-
sults, this study also showed a better overall survival in
breast cancer brain metastasis patients compared to his-
torical series looking at brain metastasis without respect
to tumor histology. In this study, controlled extracranial
disease, KPS ≥ 70, lower total radiosurgery volume, and
HER2/neu overexpression were all predictors of better
overall survival on multivariate analysis. Kased et al.
reviewed 176 patients with newly diagnosed or recurrent
breast cancer brain metastasis [19]. The median survival
for new diagnosis treated with SRS was 16.0 months and
11.7 months for recurrent tumors. Overall survival pre-
dictors that were found to be significant on multivariate
analysis were KPS ≥ 70, estrogen receptor positive tumors,
and HER2/neu overexpression. Muacevic et al. reviewed
151 patients and determined survival based on RPA status
[20]. Median survivals of 34.9, 9.1, and 7.9 months were
found for RPA classes I, II, and III, respectively. KPS ≥ 70
and RPA class I were predictors of survival on multivariate
analysis. Goyal et al. reviewed 43 patients and found a me-
dian survival of 13 months [21]. Predictors for increased
overall survival in this cohort were found to be higher
KPS score, patients with a SIR index (Score Index for Ra-
diosurgery) ≥ 8, and a single lesion.
As in our study, there have been several studies noting an
association with improved survival in patients with HER2
overexpressing tumors with CNS disease. Lower et al. first
demonstrated this finding, and studies since have suggested
that the improved survival data was based on HER2-
targeted systemic therapies [22-24]. Though HER2 overex-
pression historically portended a poor prognosis with early
distant dissemination of disease, in modern therapy it is be-
lieved to provide additional armamentarium for enhanced
systemic therapy which has conferred a survival advantage.
In our cohort of patients, we have a rather well distrib-
uted population in terms of age and stage, but the pa-
tients selected for treatment were uniformly of high
performance status (KPS ≥70). While stage had no im-
pact on CNS recurrence rates, there was an association
between stage and overall survival. Notably, patients with
stage I disease had a shorter MST, as compared to other
disease stages. Stage I patients may be less likely to
undergo brain surveillance, and if they do develop metas-
tases to the brain, this may implicate relatively more ag-
gressive tumor biology.
The median time to brain failure was 7.1 months with a
1-yr progression-free survival (PFS) of 49% in the brain. In
Figure 4 Overall survival of patients treated by GKS stratified by Breast Specific GPA.
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prior reports, 1-yr PFS has varied from 71% to 90%
[18,19]. Furthermore the presence of CNS failure was as-
sociated with increased survival in our patient cohort.
However our report had a very high percentage (46%) of
censored cases, as patients who had progressive disease
outside of the CNS generally did not undergo further sur-
veillance CNS imaging. This may partially account for the
discrepancy in outcomes, as there may be a bias in favor
of selection of patients with relatively stable systemic dis-
ease or who may be only “slowly” progressing in the brain.
The median overall survival time following GKS for our
patient cohort was 12.3 months. Reported times have
ranged from 7.8 – 20 months with improved median sur-
vival times based on various prognostic assessments
[18,20,21,25-29]. In our study, there were no patients with
an RTOG RPA of 3, and no reasonable determination
could be made regarding trends in survival between RTOG
RPA Groups 1 and 2. Sperduto et al. presented an updated
recursive partitioning analysis for brain metastases, the
Graded Prognostic Index in 2008, and subsequently built
an enhanced, BS-GPA, with findings reported in 2010 and
2011 [5,30]. In their most recent article, they reported
MSTs of 3.4 months for BS-GPA 0.0 - 1.0, 7.7 months for
BS-GPA 1.5 – 2.0, 15.1 months for BS-GPA 2.5 – 3.0 and
25.3 months for BS-GPA 3.5 – 4.0. In our cohort, patients
with a BS-GPA of 0 – 1.0 had a MST of 6.4 months (likely
improved from the Sperduto et al. report, as there were
no patients in our cohort with a score of 0) [5]. For the BS-
GPA of 1.5 - 2.0 the MST was 7.9 months, for 2.5 - 3.0 the
MST was 13.3 months, and those with a BS-GPA of 3.5 -
4.0 had a MST of 21.1 months. These findings were gener-
ally very similar to those reported in Sperduto et al. [5].
While there was no significance to the stratification of
patient outcomes based on treatment type, likely due to
this analysis being underpowered to detect this differ-
ence, there was a trend toward significance with the
GKS as a boost after surgery or as salvage after surgery
being associated with longer survival times as compared
to the other treatment types. Additional analysis in the
retrospective setting is fraught with bias. The patients
that undergo surgery are a highly selective lot, usually
chosen, because of promising features of their disease
process. For example, patients who present with delayed
metachronous metastases are more likely to undergo re-
section than patients developing metastases shortly after
disease presentation. In addition, there is bias with
regards to number of lesions, patient age, patient per-
formance status, etc. We also note a curious outcome in
our patient cohort with regards to patients who received
upfront WBRT having worse outcomes than those who
do not. Once again, there is bias here, in that patients
selected for upfront GKS often have a bias towards fewer
lesions, better KPS, younger age, and better-controlled
extracranial disease.
In conclusion, the strongest individual clinical prog-
nosticators in our cohort were the number of lesions
and age, when entered in our stepwise multivariate re-
gression model. While tumor subtype has been demon-
strated to be important in other reports, it did not hold
in our studies. In addition, performance status did not
have an impact on patient survival in our studies. How-
ever, this more than likely represents a selection bias in
favor of high performing patients within our institution.
Competing interests
The authors declare that no actual or potential conflicts of interest exist.
Authors’ contributions
JJ and DF analyzed data and drafted the manuscript. TD performed the
statistical analyses. KR, MC, JD, DM, RD, and JS reviewed and edited the
manuscript. WM and AP collected patient data. IZ conceived the study,
analyzed data, drafted, reviewed and edited the manuscript. All authors
reviewed and approved the final draft of the manuscript.
Acknowledgements
We thank the SCC-WUSM and Barnes-Jewish Hospital in St. Louis, Mo., for
the use of the Clinical Trials Core, which provided regulatory service. The
Siteman Cancer Center is supported in part by NCI Cancer Center Support
Grant #P30 CA91842.
Author details
1Department of Radiation Oncology, Washington University School of
Medicine, St. Louis, MO, USA. 2Department of Neurological Surgery,
Washington University School of Medicine, St. Louis, MO, USA. 3Department
of Radiation Oncology, Case Western Reserve University, Cleveland, USA.
4Department of Human Oncology, University of Wisconsin School of
Medicine and Public Health, Madison, WI, USA. 5Arizona Oncology Services,
Phoenix, AZ, USA.
Received: 3 October 2012 Accepted: 23 May 2013
Published: 29 May 2013
References
1. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol
2004, 22:3608–3617.
2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS: Breast cancer
metastasis to the central nervous system. Am J Pathol 2005,
167:913–920.
3. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna
WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors
in three Radiation Therapy Oncology Group (RTOG) brain metastases
trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.
4. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive
partitioning analysis (RPA) classification for brain metastases. Int J Radiat
Oncol Biol Phys 2000, 47:1001–1006.
5. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao
ST, Weil RJ, Suh J, et al: Effect of tumor subtype on survival and the
graded prognostic assessment for patients with breast cancer and brain
metastases. Int J Radiat Oncol Biol Phys 2012, 82:2111–2117.
6. Leksell L: The stereotaxic method and radiosurgery of the brain. Acta Chir
Scand 1951, 102:316–319.
7. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC,
Werner-Wasik M, Demas W, Ryu J, Bahary JP, et al: Whole brain radiation
therapy with or without stereotactic radiosurgery boost for patients with
one to three brain metastases: phase III results of the RTOG 9508
randomised trial. Lancet 2004, 363:1665–1672.
8. Mathieu D, Kondziolka D, Flickinger JC, Fortin D, Kenny B, Michaud K, Mongia S,
Niranjan A, Lunsford LD: Tumor Bed Radiosurgery after Resection of Cerebral
Metastases. Neurosurgery 2008, 62(4):817–23.
9. Limbrick DD Jr, Lusis EA, Chicoine MR, Rich KM, Dacey RG, Dowling
JL, Grubb RL, Filiput EA, Drzymala RE, Mansur DB, Simpson JR:
Combined surgical resection and stereotactic radiosurgery for
Jaboin et al. Radiation Oncology 2013, 8:131 Page 7 of 8
http://www.ro-journal.com/content/8/1/131
treatment of cerebral metastases. Surg Neurol 2009, 71:280–288.
disucssion 288–289.
10. Flickinger JC, Kondziolka D, Lunsford LD, Coffey RJ, Goodman ML, Shaw EG,
Hudgins WR, Weiner R, Harsh GR, Sneed PK, et al: A multi-institutional
experience with stereotactic radiosurgery for solitary brain metastasis.
Int J Radiat Oncol Biol Phys 1994, 28:797–802.
11. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD: Stereotactic
radiosurgery for four or more intracranial metastases. Int J Radiat Oncol
Biol Phys 2006, 64:898–903.
12. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N: Single
dose radiosurgical treatment of recurrent previously irradiated primary
brain tumors and brain metastases: final report of RTOG protocol 90–05.
Int J Radiat Oncol Biol Phys 2000, 47:291–298.
13. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M,
Oya N, Hirota S, Shioura H, et al: Stereotactic radiosurgery plus whole-
brain radiation therapy vs stereotactic radiosurgery alone for treatment
of brain metastases: a randomized controlled trial. JAMA 2006,
295:2483–2491.
14. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E,
Syrjanen K: Prediction of outcome after first recurrence of breast cancer.
Eur J Surg 1992, 158:13–18.
15. Bloom HJ, Richardson WW, Harries EJ: Natural history of untreated
breast cancer (1805–1933). Comparison of untreated and treated
cases according to histological grade of malignancy. Br Med J 1962,
2:213–221.
16. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE,
Schmitz PI: Identification of prognostic factors in patients with brain
metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys
1999, 43:795–803.
17. Padovani L, Muracciole X, Regis J: gamma knife radiosurgery of brain
metastasis from breast cancer. Prog Neurol Surg 2012, 25:156–162.
18. Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, Brufsky
AM, Flickinger JC, Lunsford LD: Stereotactic radiosurgery as primary and
salvage treatment for brain metastases from breast cancer. Clinical
article. J Neurosurg 2011, 114:792–800.
19. Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS,
Wara WM, Sneed PK: Gamma Knife radiosurgery for brain metastases
from primary breast cancer. Int J Radiat Oncol Biol Phys 2009,
75:1132–1140.
20. Muacevic A, Kreth FW, Tonn JC, Wowra B: Stereotactic radiosurgery for
multiple brain metastases from breast carcinoma. Cancer 2004,
100:1705–1711.
21. Goyal S, Prasad D, Harrell F Jr, Matsumoto J, Rich T, Steiner L: Gamma knife
surgery for the treatment of intracranial metastases from breast cancer.
J Neurosurg 2005, 103:218–223.
22. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G,
Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG: Trastuzumab
prolongs overall survival in patients with brain metastases from Her2
positive breast cancer. J Neurooncol 2007, 85:311–317.
23. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH,
Chie EK, et al: Clinical outcome of central nervous system metastases
from breast cancer: differences in survival depending on systemic
treatment. J Neurooncol 2012, 106:303–313.
24. Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK:
Increased rate of brain metastasis with trastuzumab therapy
not associated with impaired survival. Clin Breast Cancer 2003,
4:114–119.
25. Akyurek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA,
Shiu AS, Maor MH, Woo SY: Stereotactic radiosurgical treatment of
cerebral metastases arising from breast cancer. Am J Clin Oncol 2007,
30:310–314.
26. Amendola BE, Wolf AL, Coy SR, Amendola M, Bloch L: Gamma knife
radiosurgery in the treatment of patients with single and multiple
brain metastases from carcinoma of the breast. Cancer J 2000,
6:88–92.
27. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Treatment of
cerebral metastases from breast cancer with stereotactic radiosurgery.
Strahlenther Onkol 2004, 180:590–596.
28. Firlik KS, Kondziolka D, Flickinger JC, Lunsford LD: Stereotactic
radiosurgery for brain metastases from breast cancer. Ann Surg Oncol
2000, 7:333–338.
29. Lederman G, Wronski M, Fine M: Fractionated radiosurgery for brain
metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat 2001,
65:145–154.
30. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic
index and comparison to three other indices for patients with brain
metastases: an analysis of 1,960 patients in the RTOG database. Int J
Radiat Oncol Biol Phys 2008, 70:510–514.
doi:10.1186/1748-717X-8-131
Cite this article as: Jaboin et al.: Survival following gamma knife
radiosurgery for brain metastasis from breast cancer. Radiation Oncology
2013 8:131.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jaboin et al. Radiation Oncology 2013, 8:131 Page 8 of 8
http://www.ro-journal.com/content/8/1/131
